Table 1. Percentage of Subjects Developing Serum Hemagglutination-inhibition Antibody Titers ≥1∶40 (or 1∶32) by Vaccine HA Dosage after Vaccinations with Monovalent Inactivated Influenza A Virus Vaccines.1 .
| Subtype and Vaccine2 | Mfr.3 | % with Titer ≥1∶40 by Vaccine HA Dosage4 | ||||||
| 3.8 µg | 7.5 µg | 15 µg | 30 µg | 45 µg | 90 µg | Ref. | ||
| H5N1 | ||||||||
| Vietnam/045 | SP | 6.5 | 17 | 34 | 46 | 2 | ||
| Vietnam/04 | GSK | 17 | 16 | 35 | 43 | 3 | ||
| Vietnam/04 | SP | 16 | 56 | 4 | ||||
| Vietnam/04 | SP | 2 | 0 | 13 | 26 | 58 | ||
| Vietnam/04 | SP | 35 | 68 | |||||
| Vietnam/04 | CSL | 37 | 37 | 7 | ||||
| Vietnam/04 | Novartis | 24 | 18 | 29 | 8 | |||
| Vietnam/04 | SP (Lyon) | 43 | 44 | 52 | 9 | |||
| Vietnam/046 | SP | 43 | 108 | |||||
| Indo/056 | SP | 51 | 108 | |||||
| Indo/05 | GSK | 17 | 11 | |||||
| H7N7 | ||||||||
| Mallard/00 | SP | 0 | 0 | 0 | 4 | 128 | ||
| H9N2 | ||||||||
| HK/G1/99 | GSK | 67 | 13 | |||||
| HK/G1/99 | Wyeth | 11 | 15 | -8 | ||||
| CK/G9/97 | Novartis | 67 | 58 | 50 | 75 | 148 | ||
| H1N1 | ||||||||
| A/Cal/09 Vac | SP | |||||||
| (ages 18–64 years)7 | 95 | 98 | 100 | 348 | ||||
| (ages 3–9 years) | 97 | 99 | 358 | |||||
| (ages 0.5–3 years) | 91 | 99 | ||||||
| A/Cal/09 Vac | CSL | 368 | ||||||
| (ages 18–49 years)7 | 97 | 98 | ||||||
1
All are after two doses of subunit vaccine 3–4 weeks apart and all trials were in healthy adults aged 18 to 49 except as noted.
2
Vaccine subtype and strain.
3
Manufacturer: SP – Sanofi Pasteur; GSK – GlaxoSmithKline, Wyeth – batch donated to NIAID.
4
Percents are for clinical trials reporting results for the dosages listed. Dosages are as determined in single radial immunodiffusion assays (SRID).
5
Data are FDA reanalysis of trial results reported in reference 2.
6
Data provided by Belshe, RB, et al. (ref 10).
7
Data are after one dose for ages 18–64 and 18–49 and after two doses for 3–9 and 0.5–3.
8
Clinical trial results for vaccines used in this study, references 5, 6, 10 were with the USA licensed H5/VN/04 vaccine.